Right, that makes sense on the face of it. However, with the kind of valuations Divi’s has currently I just feel like I would need more detail than that. None of the competitors I mentioned have significant issues with quality and are world class pharma players. Is it that they all have effectively compromised value by not sticking to pure play API? Else why would Dr Reddy, Cipla, and Sun be at 20-30x P/E while Divi’s is at 50x+
| Subscribe To Our Free Newsletter |
